IP Library › Granted Patent US 12,226,428
Granted Patent B2
US 12,226,428 · App. 18/330,293 · Granted Feb 18, 2025

Catecholamine prodrugs for use in the treatment of Parkinson's disease

Inventors: Klaus Gjervig Jensen (Valby, DK); Lisbet Kværnø (Valby, DK); Morten Jørgensen (Valby, DK); Martin Juhl (Valby, DK)
Assignee: H. Lundbeck A/S
A61K31/706A61K31/473A61P25/00C07D405/12C07D405/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,226,428
App. No.
18/330,293
Granted
Feb 18, 2025
Kind
B2
Abstract

The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease. Accordingly, the present invention relates to compounds of formula (Id) wherein R1 is H and R2 is selected from one of the substituents (i) and (ii) below; or R1 is selected from one of the substituents (i) and (ii) below and R2 is H; or R1 and R2 are both represented by substituent (i) below; or R1 and R2 are both represented by substituent (ii) below; or R1 is substituent (i) and R2 is substituent (ii); or R1 is substituent (ii) and R2 is substituent (i); wherein * indicates the attachment point; and wherein the carbon atom at the attachment point on substituent (i) is in the S-configuration; or a pharmaceutically acceptable salt thereof.

Claims (30)

1. A pharmaceutical composition comprising a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof for the treatment of Parkinson's disease, and one or more pharmaceutically acceptable excipients,

wherein the compound is selected from the group consisting of:

(Id-ia): (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid;

(Id-ib): (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid;

(Id-iia): (4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl hydrogen sulfate;

(Id-iib): (4aR,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-yl) hydrogen sulfate;

(Id-iab): (2S,2'S,3S,3'S,4S,4'S,5R,5′R,6S,6'S)-6,6′-(((4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl)bis(oxy))bis(3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid); and

(Id-iiab): (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diyl bis(hydrogen sulfate).

2. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition is an oral pharmaceutical composition.

3. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition is a solid oral dosage form.

4. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition is a tablet or a capsule.

5. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition further comprises another agent which is useful in the treatment of a neurodegenerative disease or disorder.

6. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition further comprises another agent which is useful in the treatment of Parkinson's disease.

7. The pharmaceutical composition according to claim 1 ,

wherein said compound is the compound represented by formula (Id-ia) below

8. The pharmaceutical composition according to claim 1 , wherein said compound is the compound represented by formula (Id-ib) below

9. The pharmaceutical composition according to claim 1 , wherein said compound is the compound represented by formula (Id-iab) below

10. The pharmaceutical composition according to claim 7 , wherein said pharmaceutical composition is an oral pharmaceutical composition.

11. The pharmaceutical composition according to claim 8 , wherein said pharmaceutical composition is an oral pharmaceutical composition.

12. The pharmaceutical composition according to claim 9 , wherein said pharmaceutical composition is an oral pharmaceutical composition.

13. The pharmaceutical composition according to claim 7 , wherein said pharmaceutical composition is a solid oral dosage form.

14. The pharmaceutical composition according to claim 8 , wherein said pharmaceutical composition is a solid oral dosage form.

15. The pharmaceutical composition according to claim 9 , wherein said pharmaceutical composition is a solid oral dosage form.

16. The pharmaceutical composition according to claim 7 , wherein said pharmaceutical composition is a tablet or a capsule.

17. The pharmaceutical composition according to claim 8 , wherein said pharmaceutical composition is a tablet or a capsule.

18. The pharmaceutical composition according to claim 9 , wherein said pharmaceutical composition is a tablet or a capsule.

19. The pharmaceutical composition according to claim 7 , wherein said pharmaceutical composition further comprises another agent which is useful in the treatment of Parkinson's disease.

20. The pharmaceutical composition according to claim 8 , wherein said pharmaceutical composition further comprises another agent which is useful in the treatment of Parkinson's disease.

21. The pharmaceutical composition according to claim 9 , wherein said pharmaceutical composition further comprises another agent which is useful in the treatment of Parkinson's disease.

22. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is (4aR,10aR)-1-propyl-7-((triisopropylsilyl)oxy)-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ol.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2023
From: JENSEN, KLAUS GJERVIG; KVAERNØ, LISBET; JØRGENSEN, MORTEN; JUHL, MARTIN
To: H. LUNDBECK A/S
Reel/Frame 064301/0730 →
Priority Claims (1)
DK PA201700674 · Nov 24, 2017 · national
Continuity (4)
Continuation 17386686 · Jul 28, 2021
Continuation 16872802 · May 12, 2020
Continuation 16198917 · Nov 23, 2018
Related Publication 20240156851A1 · May 16, 2024
References Cited (170)
US 3132171A · Plaut · 1964 [cited by applicant]
US 4543256A · Neumeyer · 1985 [cited by applicant]
US 4565818A · Nordmann et al. · 1986 [cited by applicant]
US 4692453A · Seiler · 1987 [cited by applicant]
US 5073547A · Casagrande et al. · 1991 [cited by applicant]
US 5747513A · Montanari et al. · 1998 [cited by applicant]
US 5885988A · Neumann et al. · 1999 [cited by applicant]
US 5955468A · Markstein · 1999 [cited by applicant]
US 8129530B2 · Jorgensen et al. · 2012 [cited by applicant]
US 10729710B2 · Jensen · 2020 [cited by examiner]
US 11104697B2 · Juhl · 2021 [cited by examiner]
US 11110110B2 · Jensen · 2021 [cited by examiner]
US 11111263B2 · Juhl et al. · 2021 [cited by applicant]
US 11130775B2 · Jensen · 2021 [cited by examiner]
US 11168056B2 · Jacobsen et al. · 2021 [cited by applicant]
US 11707476B2 · Jensen · 2023 [cited by examiner]
US 11827665B2 · Juhl · 2023 [cited by examiner]
US 11851456B2 · Juhl et al. · 2023 [cited by applicant]
US 11858954B2 · Jensen · 2024 [cited by examiner]
US 11866410B2 · Jacobsen et al. · 2024 [cited by applicant]
US 20090062324A1 · Jorgensen et al. · 2009 [cited by applicant]
US 20090124651A1 · Jorgensen et al. · 2009 [cited by applicant]
US 20120077836A1 · Wilkstrom et al. · 2012 [cited by applicant]
US 20170335357A1 · Divi et al. · 2017 [cited by applicant]
US 20200338102A1 · Balmer et al. · 2020 [cited by applicant]
US 20200369615A1 · Jacobsen et al. · 2020 [cited by applicant]
US 20200369705A1 · Juhl et al. · 2020 [cited by applicant]
US 20200369706A1 · Juhl et al. · 2020 [cited by applicant]
US 20200392176A1 · Jensen et al. · 2020 [cited by applicant]
US 20220024875A1 · Jacobsen et al. · 2022 [cited by applicant]
US 20220024962A1 · Jensen et al. · 2022 [cited by applicant]
US 20220185839A1 · Juhl et al. · 2022 [cited by applicant]
US 20220194978A1 · Juhl et al. · 2022 [cited by applicant]
US 20220213040A1 · Jorgensen et al. · 2022 [cited by applicant]
US 20220213071A1 · Jorgensen et al. · 2022 [cited by applicant]
US 20220213136A1 · Jorgensen et al. · 2022 [cited by applicant]
US 20220220077A1 · Jorgensen et al. · 2022 [cited by applicant]
US 20220257623A1 · Jensen et al. · 2022 [cited by applicant]
US 20240018107A1 · Jacobsen et al. · 2024 [cited by applicant]
US 20240025857A1 · Jorgensen et al. · 2024 [cited by applicant]
US 20240190909A1 · Jensen et al. · 2024 [cited by applicant]
CN 102746351A · 2012 [cited by applicant]
CN 105218606A · 2016 [cited by applicant]
EP 0352815A1 · 1990 [cited by applicant]
GB 2192394A · 1998 [cited by applicant]
JP S60172975A · 1985 [cited by applicant]
JP 2010536889A · 2010 [cited by applicant]
WO WO9012574A1 · 1990 [cited by applicant]
WO WO9703054A1 · 1997 [cited by applicant]
WO WO9838155A1 · 1998 [cited by applicant]
WO WO0047571A1 · 2000 [cited by applicant]
WO WO0136428A1 · 2001 [cited by applicant]
WO WO0176602A1 · 2001 [cited by applicant]
WO WO0178713A1 · 2001 [cited by applicant]
WO WO0213827A1 · 2002 [cited by applicant]
WO WO0214279A1 · 2002 [cited by applicant]
WO WO02100377A1 · 2002 [cited by applicant]
WO WO03006458A1 · 2003 [cited by applicant]
WO WO03013532A1 · 2003 [cited by applicant]
WO WO03074511A1 · 2003 [cited by applicant]
WO WO03080074A1 · 2003 [cited by applicant]
WO WO2004052841A1 · 2004 [cited by applicant]
WO WO2005062894A2 · 2005 [cited by applicant]
WO WO2006012640A2 · 2006 [cited by applicant]
WO WO2006056604A1 · 2006 [cited by applicant]
WO WO2009026934A1 · 2009 [cited by applicant]
WO WO2009026935A1 · 2009 [cited by applicant]
WO WO2009156458A1 · 2009 [cited by applicant]
WO WO2010097091A1 · 2010 [cited by applicant]
WO WO2010097092A1 · 2010 [cited by applicant]
WO WO2013020979A1 · 2013 [cited by applicant]
WO WO2013034119A1 · 2013 [cited by applicant]
WO WO2015067927A1 · 2015 [cited by applicant]
WO WO2016065019A1 · 2016 [cited by applicant]
WO WO2017184871A1 · 2017 [cited by applicant]
WO WO2019101917A1 · 2019 [cited by applicant]
WO WO2020234271A1 · 2020 [cited by applicant]
U.S. Appl. No. 16/198,917, filed Nov. 23, 2018, Granted, U.S. Pat. No. 10,729,710. [cited by applicant]
U.S. Appl. No. 16/872,802, filed May 12, 2020, Granted, U.S. Pat. No. 11,110,110. [cited by applicant]
U.S. Appl. No. 17/386,686, filed Jul. 28, 2021, Granted, U.S. Pat. No. 11,707,476. [cited by applicant]
U.S. Appl. No. 16/876,843, filed May 18, 2020, Granted, U.S. Pat. No. 11,104,697. [cited by applicant]
U.S. Appl. No. 17/385,166, filed Jul. 26, 2021, Granted, U.S. Pat. No. 11,827,665. [cited by applicant]
U.S. Appl. No. 16/876,878, filed May 18, 2020, Granted, U.S. Pat. No. 11,111,263. [cited by applicant]
U.S. Appl. No. 17/391,439, filed Aug. 2, 2021, Granted, U.S. Pat. No. 11,851,456. [cited by applicant]
U.S. Appl. No. 18/507,662, filed Nov. 13, 2023, Pending. [cited by applicant]
U.S. Appl. No. 16/876,908, filed May 18, 2020, Granted, U.S. Pat. No. 11,130,775. [cited by applicant]
U.S. Appl. No. 17/392,970, filed Aug. 3, 2021, Granted, U.S. Pat. No. 11,858,954. [cited by applicant]
U.S. Appl. No. 18/511,231, filed Nov. 16, 2023, Pending. [cited by applicant]
U.S. Appl. No. 16/876,966, filed May 18, 2020, Granted, U.S. Pat. No. 11,168,056. [cited by applicant]
U.S. Appl. No. 17/495,997, filed Oct. 7, 2021, Granted, U.S. Pat. No. 11,866,410. [cited by applicant]
U.S. Appl. No. 18/359,136, filed Jul. 26, 2023, Published, 2024-0018107. [cited by applicant]
U.S. Appl. No. 17/606,313, filed Oct. 25, 2021, Published, 2022-0213136. [cited by applicant]
U.S. Appl. No. 17/606,319, filed Oct. 25, 2021, Published, 2022-0213071. [cited by applicant]
U.S. Appl. No. 17/606,332, filed Oct. 25, 2021, Published, 2022-0213040. [cited by applicant]
U.S. Appl. No. 17/606,303, filed Oct. 25, 2021, Published, 2022-0220077. [cited by applicant]
U.S. Appl. No. 18/036,596, filed May 11, 2023, Published, 2024-0025857. [cited by applicant]
PCT/EP2018/082361, Feb. 22, 2019, International Search Report and Written Opinion. [cited by applicant]
PCT/EP2020/063908, Sep. 11, 2020, International Search Report and Written Opinion. [cited by applicant]
PCT/EP2020/063909, Jul. 2, 2020, International Search Report and Written Opinion. [cited by applicant]
PCT/EP2020/063910, Jul. 14, 2020, International Search Report and Written Opinion. [cited by applicant]
PCT/EP2020/063913, Jul. 15, 2020, International Search Report and Written Opinion. [cited by applicant]
PCT/EP2020/063914, Jul. 14, 2020, International Search Report and Written Opinion. [cited by applicant]
PCT/EP2020/063915, Jul. 13, 2020, International Search Report and Written Opinion. [cited by applicant]
PCT/EP2020/063916, Sep. 28, 2020, International Search Report and Written Opinion. [cited by applicant]
PCT/EP2020/063918, Aug. 10, 2020, International Search Report and Written Opinion. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2018/082361 mailed Feb. 22, 2019. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2020/063909 mailed Jul. 2, 2020. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2020/063915 mailed Jul. 13, 2020. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2020/063910 mailed Jul. 14, 2020. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2020/063914 mailed Jul. 14, 2020. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2020/063913 mailed Jul. 15, 2020. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2020/063918 mailed Aug. 10, 2020. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2020/063908 mailed Sep. 11, 2020. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2020/063916 mailed Sep. 28, 2020. [cited by applicant]
Ahari et al., A direct stereoselective approach to trans-2,3-disubstituted piperidines: application in the synthesis of 2-Epi-CP-99,994 and (+)-epilupinine. Org Lett. Jun. 19, 2008;10(12):2473-6. doi: 10.1021/01800722a.… [cited by applicant]
Alexander et al., Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. Jul. 1990;13(7):266-71. [cited by applicant]
Atkinson et al., Derivatives of apomorphine and of other N-substituted norapomorphines. J Pharm Sci. Nov. 1976;65(11):1682-5. [cited by applicant]
Banker et al., Modern Pharmaceuticals. Third Edition, Revised and Expanded. Marcel Dekker, Inc., New York, 1996. p. 596. [cited by applicant]
Bibbiani et al., Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol. Mar. 2005;192(1):73-8. [cited by applicant]
Billeter et al., 8-Hydroxyflavonoid Glucuronides from Malva Sylvestris. Phytochemistry. 1991; 30(3):987-90. [cited by applicant]
Brown et al., Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding characterization at D2/D3 receptors and elucidation of a pharmacoph… [cited by applicant]
Byrn et al., Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations. Pharmaceutical Research. 1995;12(7):945-54. [cited by applicant]
Caira, Crystalline Polymorphism of Organic Compounds. Design of Organic Solids. Topics in Current Chemistry. 1998(198):163-208. [cited by applicant]
Campbell et al., Behavioral effects of (−)10,11-methylenedioxy-N-n-propylnoraporphine, an orally effective long-acting agent active at central dopamine receptors, and analogous aporphines. Neuropharmacology. Oct. 1982;2… [cited by applicant]
Cannon et al., N-Alkyl derivatives of trans-6,7-dihydroxy-1,2,3,4,4a,5,10,10b-octahyrobenzo[g]quinoline A congener of apomorphine lacking the non-oxygenated aromatic ring. J. Heterocyclic Chem. Nov. 1980;17:1633-1636. [cited by applicant]
Cavero et al., Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy. J Pharmacol Toxicol Methods. Mar.-Apr. 2014;69(2):150-61. doi: 10.1016/j.vascn.2013.12.004. Ep… [cited by applicant]
Clarke, Recent developments in the homogeneous hydrogenation of carboxylic acid esters. Catal. Sci. Technol. Sep. 25, 2012;2:2418-23. [cited by applicant]
David et al., Control of catalytic debenzylation and dehalogenation reactions during liquid-phase reduction by H [cited by applicant]
Delong, Primate models of movement disorders of basal ganglia origin. Trends Neurosci. Jul. 1990;13(7):281-5. [cited by applicant]
Di Stefano et al., Antiparkinson prodrugs. Molecules. Jan. 16, 2008;13(1):46-68. [cited by applicant]
Elger et al., Estrogen sulfamates: a new approach to oral estrogen therapy. Reprod Fertil Dev. 2001;13(4):297-305. doi: 10.1071/rd01029. [cited by applicant]
Elger et al., Novel oestrogen sulfamates: a new approach to oral hormone therapy. Expert Opin Investig Drugs. Apr. 1998;7(4):575-89. doi: 10.1517/13543784.7.4.575. [cited by applicant]
Elger et al., Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. J Steroid Biochem Mol Biol. Dec. 1995;55(3-4):395-403. doi: 10.1016/0960-0760(95)… [cited by applicant]
Fan et al., Differential effects of pro-BDNF on sensory neurons after sciatic nerve transection in neonatal rats. Eur J Neurosci. May 2008;27(9):2380-90. doi: 10.1111/j.1460-9568.2008.06215.x. Epub Apr. 22, 2008. [cited by applicant]
Fan et al., Modifications of the isonipecotic acid fragment of SNS-032: analogs with improved permeability and lower efflux ratio. Bioorg Med Chem Lett. Dec. 1, 2008;18(23):6236-9. doi: 10.1016/j.bmcl.2008.09.099. Epub … [cited by applicant]
Fumeaux et al., First synthesis, characterization, and evidence for the presence of hydroxycinnamic acid sulfate and glucuronide conjugates in human biological fluids as a result of coffee consumption. Org Biomol Chem. … [cited by applicant]
Gerfen et al., D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. Dec. 7, 1990;250(4986):1429-32. [cited by applicant]
Giardina et al., Adrogolide HCI (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16. [cited by applicant]
Goswami et al., Intestinal absorption and metabolism of retinoyl beta-glucuronide in humans, and of 15-[14C]-retinoyl beta-glucuronide in rats of different vitamin A status. J Nutr Biochem. Dec. 2003;14(12):703-9. [cited by applicant]
Grosset et al., Inhaled dry powder apomorphine (VR040) for ‘off’ periods in Parkinson's disease: an in-clinic double-blind dose ranging study. Acta Neurol Scand. Sep. 2013;128(3):166-71. doi: 10.1111/ane.12107. Epub Mar… [cited by applicant]
Hauser et al., Sublingual apomorphine (APL-130277) for the acute conversion of Off to On in Parkinson's disease. Mov Disord. Sep. 2016;31(9):1366-72. Epub Jul. 19, 2016. [cited by applicant]
Knobloch et al., β-Keto Esters Derived from 2-(Trimethylsilyl) ethanol: An Orthogonal Protective Group for β-Keto Esters. Synthesis 2008.14 (2008): 2229-2246. [cited by applicant]
Kotsuki et al., Highly practical, enantiospecific synthesis of the cyclohexyl fragment of the immunosuppressant FK-506. J Org Chem. Aug. 1992;57(18):5036-40. [cited by applicant]
Kummerer, K. Pharmaceuticals in the Environment. Annu. Rev. Environ. Resour. 2010. 35:57-75. doi: 10.1146/annurev-environ-052809-161223. [cited by applicant]
Kuznetsova, Qualitative X-ray phase analysis—Methodological guidelines. Irkutsk State University, General Physics Department. 2005;6 pages. [cited by applicant]
Levin et al., Cognitive and neuropsychiatric disorders in extrapyramidal diseases. Neurology, Neuropsychiatry, Psychosomatics. 2012;4(2S):22-30. https://doi.org/10.14412/2074-2711-2012-2505. [cited by applicant]
Liu et al., A novel synthesis and pharmacological evaluation of a potential dopamine D1/D2 agonist: 1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diol. Bioorg Med Chem. Mar. 15, 2008;16(6):3438-44. doi: 10… [cited by applicant]
Liu et al., Extremely potent orally active benzo[g]quinoline analogue of the dopaminergic prodrug: 1-propyl-trans-2,3,4,4a,5,7,8,9,10,10a-decahydro-1H-benzo-[g]quinolin-6-one [corrected]. J Med Chem. Feb. 23, 2006;49(4)… [cited by applicant]
Loozen et al., An approach to the synthesis of [2] benzopyrano [3, 4?c] pyrroles; alternative dopaminergic molecules. Recueil des Travaux Chimiques des Pays?Bas. 1982;101(9):298-310. [cited by applicant]
Malmquist et al., The synthesis of tritiated (R)-2-methoxy-N-n-propyl-nor-apomorphine (MNPA). J Label Compd Radiopharm. Sep. 2007;50(13):1211-1214. [cited by applicant]
Mironov, The Guidelines for Preclinical Trials of Medicinal Products. Grif & Co. Moscow, Russia. 2012. 941 pages. [cited by applicant]
Morissette et al., High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev. Feb. 23, 2004;56(3):275-300. doi: 10.1016/j.addr.2003.10.020. [cited by applicant]
Nolen et al., Budesonide-beta-D-glucuronide: a potential prodrug for treatment of ulcerative colitis. J Pharm Sci. Jun. 1995;84(6):677-81. [cited by applicant]
Poewe et al., Parkinson disease. Nat Rev Dis Primers. Mar. 23, 2017;3:17013. [cited by applicant]
Przedborski et al., Neurodegeneration: What is it and where are we? J Clin Invest. 2003;111(1):3-10. https://doi.org/10.1172/JCI17522. [cited by applicant]
Reutov et al., Organic Chemistry: Manual for Chemical Students and Post-Graduates. 1999; 903-904; 905; 1738-1739 (with reference to N. Kornblum, 1963). [cited by applicant]
Reutov et al., Organic Chemistry: textbook for students of chemical specialties and graduate students. 1999. Chapter 27, Section 27.9.1.c., 1999;6 pages. [cited by applicant]
Rothman et al., Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. Dec. 5, 2000;102(23):2836-41. [cited by applicant]
Sozio et al., Designing prodrugs for the treatment of Parkinson's disease. Expert Opin Drug Discov. May 2012;7(5):385-406. Epub Apr. 12, 2012. [cited by applicant]
Sprenger et al., Management of motor and non-motor symptoms in Parkinson's disease. CNS Drugs. Apr. 2013;27(4):259-72. [cited by applicant]
Stain-Texier et al., Intestinal absorption and stability of morphine 6-glucuronide in different physiological compartments of the rat. Drug Metab Dispos. May 1998;26(5):383-7. [cited by applicant]
Sun et al., Oral bioavailability and brain penetration of (−)-stepholidine, a tetrahydroprotoberberine agonist at dopamine D(1) and antagonist at D(2) receptors, in rats. Br J Pharmacol. Nov. 2009;158(5):1302-12. Epub S… [cited by applicant]
Szajewska, H. Evidence-based medicine and clinical research: both are needed, neither is perfect. Ann Nutr Metab. 2018;72 Suppl 3:13-23. doi: 10.1159/000487375. Epub Apr. 9, 2018. PMID: 29631266. [cited by applicant]
Ugrumov M.V., Development of preclinical diagnosis and preventive treatment of neurodegenerative diseases. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(11):4-14. Russian. doi: 10.17116/jnevro20151151114-14. [cited by applicant]
Wesserling et al., Will in vitro tests replace animal models in experimental oncology? J Tissue Scie Eng. 2011; 2:102e. doi:10.4172/2157-7552.1000102e. [cited by applicant]
Wolff, M.E. Burger's Medicinal Chemistry and Drug Discovery. vol. 1, Principles and Practice, Fifth Edition. John Wiley & Sons 1995. pp. 975-977. [cited by applicant]
Yu, Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. May 16, 2001;48(1):27-42. doi: 10.1016/s0169-409x(01)00098-9. [cited by applicant]
Zhang et al., Flavonoid metabolism: the synthesis of phenolic glucuronides and sulfates as candidate metabolites for bioactivity studies of dietary flavonoids. Tetrahedron. 2012; 68:4194-4201. [cited by applicant]
Fernandez et al., Synthesis and biological studies of glycosyl dopamine derivatives as potential antiparkinsonian agents. Carbohydr Res. Aug. 7, 2000;327(4):353-65. doi: 10.1016/s0008-6215(00)00073-2. [cited by applicant]
Yujian et al., Prodrug: Design and Clinical Application. Int J Pharm Res. Oct. 2008;5(35): 377-380, 387. [cited by applicant]
Cited By (6)
US 12,384,765 US 12,391,650 US 12,398,106 US 12,398,169 US 12,421,271 US 12,479,801